WAUWATOSA, Wis. – GE Healthcare has expanded its mobile and digital offerings with the acquisition of monitoring technology company Monica Healthcare. The U.K.-based Monica Healthcare makes wearable wireless fetal monitoring devices. “Through this acquisition, we will combine the incredible expertise and mobile-digital innovation from the Monica team with GE Healthcare’s longstanding industry leadership and customer focus—with more than 100,000 patients impacted just last year,” said Tammy Noll, general manager of GE Healthcare’s maternal-infant care division, in a statement. GE Healthcare has been Monica Healthcare’s North American distribution partner for the Novii Wireless Patch System, a single-use patch that monitors maternal heart rate, fetal heart rate and uterine activity.
Mango Health partners with Express Scripts
SAN FRANCISCO – mHealth company Mango Health has announced a long-term operating partnership with Express Scripts, which will include a new daily health management platform to improve health outcomes. Through the partnership, Mango Health’s mobile apps will be available to Express Scripts’ clients. “Mango Health’s success in keeping patients engaged in their care through fun, user-friendly mobile applications is a natural extension of the care our pharmacists provide to our members,” said Glen Stettin, senior vice president and chief innovation officer at Express Scripts, in a statement. The partnership will provide Express Scripts members with in-app support and advice from specialists in more than 20 specialties; pre-populated medication lists; prescription refills; customized alerts; and more. In addition to the partnership, Express Scripts has made a strategic investment in Mango Health.
Low-cost devices fail to improve adherence, study shows
CHICAGO – Medication adherence for patients with chronic diseases is not improved by the use of low-cost reminder devices, according to a recent study published in JAMA Internal Medicine.
“Low-cost reminder devices did not improve adherence among non-adherent patients who were taking up to three medications to treat common chronic conditions,” said the study’s authors.
The goal of the trial was optimal adherence to all eligible medications among patients with chronic diseases during 12 months of follow-up.
Secondary outcomes included optimal adherence to cardiac medications among patients with chronic diseases, as well as optimal adherence to antidepressants.
The four-arm, block-randomized clinical trial involved 53,480 enrollees of CVS Caremark, a pharmacy benefit manager, across the U.S. Participants were 18-64 years of age taking one to three oral medications for long-term use.
Patients were randomized to receive in the mail a pill bottle strip with toggles, a digital timer cap or a standard pillbox. The control group received neither notification nor a device.
“There was no statistically significant difference in the odds of optimal adherence between the control and any of the devices,” said the authors.
While the study found the low-cost devices did not improve adherence, the authors said they might be more effective if coupled with interventions to ensure consistent use.